We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves Novartis’ Signifor, HGS’ Raxibacumab, Ariad’s Iclusig
FDA Approves Novartis’ Signifor, HGS’ Raxibacumab, Ariad’s Iclusig
December 21, 2012
The FDA has approved Novartis’ Signifor, a twice-daily injection for Cushing’s disease patients who have not responded to, or cannot be treated with, surgery.